Golodirsen
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 77 publications
Exon-skipping therapies for DMD in Kazakhstan: Progress and challenges.
Journal: Journal of neuromuscular diseases
Published: August 27, 2026
RNA Therapeutics Targeting Skeletal Muscle: Emerging Antisense and Gene-Modifying Strategies.
Journal: Biomolecules
Published: April 26, 2026
Advancements from the EVOLVE study for assessing real-world experience with eteplirsen, golodirsen and casimersen for the treatment of DMD.
Journal: Journal of comparative effectiveness research
Published: April 10, 2026
Treatment advances for Duchenne muscular dystrophy.
Journal: Current opinion in pediatrics
Published: April 01, 2026
A Real-World Target Trial Emulation of Eteplirsen, Casimersen, and Golodirsen to Evaluate Survival Among Patients with Duchenne Muscular Dystrophy.
Journal: Advances in therapy
Published: December 08, 2025
Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions.
Journal: Frontiers in pharmacology
Published: October 07, 2025
The Utilization, Reimbursement, and Cost of Targeted Therapies for Duchenne Muscular Dystrophy (DMD) in US Medicaid Programs: A Descriptive Trend Analysis from 2017 to 2022.
Journal: Pharmaceutical medicine
Published: September 09, 2025
In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: July 28, 2025
Evolution and Breakthroughs in Exon Skipping and Splice Modulation: From Inception to Clinical Success.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: July 28, 2025
Systemic Injection of Peptide-PMOs into Humanized DMD Mice and Detection by RT-PCR and ELISA.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: July 28, 2025
Last Updated: 09/26/2026